ARCHIVES

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

This article is from The Cancer Letter archive.

Vol. 19 No. 02 | January 8, 1993

Download PDF Visit The Full Archive

Related Articles

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

April 6, 2012

Oxford Univ. Receives Funds To Create Drug Design Center.

October 6, 2000

Majority Of U.S. Cancer Patients Receive High-Quality Care, ASCO Study Finds

July 29, 2005

Ohio Judge Fines CareToLive Prostate Cancer Group That Sought The Cancer Letter’s Confidential Source Material On Provenge.

February 29, 2008

Insulin For Diabetes Increases Risk Of Colorectal Cancer

December 31, 2004